Kumar Mahendra, Baruah Upasana, Begum Dimpy, Barmon Debabrata, Nath Jyotiman, Khanikar Duncan, Bassetty Karthik Chandra
Department of gynaecological oncology, Dr B Borooah cancer Institute, Guwahati, Assam, India.
Department of Radiation oncology, Dr. Bhubaneswar Borooah cancer institute, Guwahati, Assam, India.
Eur J Obstet Gynecol Reprod Biol X. 2024 May 6;22:100314. doi: 10.1016/j.eurox.2024.100314. eCollection 2024 Jun.
Recurrence rates of FIGO stage IB-IIA and IIB-IVA cervical cancer 28-64 respectively. There is a scarcity of data on the recurrence recurrence pattern for unusual sites and theirrecurrence pattern for unusual sites and its association with survival and prognosis.
To study overall survival in patients with distant metastasis compared to local and regional nodal metastasis.
A retrospective study was done from 1/1/2017 to 30/12/22. Cervical cancer patients post primary treatments were included. Survival was analyzed with respect to 3 groups local, regional nodalconducted from 1/1/2017 to 30/12/22. Cervical cancer patients who had received primary post-primary treatments were included. Survival was analyzed with respect to three groups: local, regional nodal, and distant metastasis.
225 patients had recurrences post-completion of primary treatment, of which 105 (46.6%)(46.6 %) had local, 46 (20.4%)(20.4 %) had regional nodal, and 74 (33.3 %) had distant recurrences. The median time for recurrence in local, regional nodal, and atypical recurrences were 9, 9, and 13 months (p value - <0.05), respectively. Treatment included systemic chemotherapy 122 (54.2 %), metronomic therapy 19 (8.4 %), palliative radiotherapy 44 (19.5 %), palliative surgery 8 (3.5 %) and best supportive care 30 (13.3 %) patients. Median Time to treatment-death of patients after recurrence in local, nodal and distant recurrences was 17.0 months, 18.0 months and 10.0 months respectively (p value - < 0.05). Overall Survival of patients after primary treatment with local, nodal and distant recurrences was 35.0 months, 47.0 months and 50.0 months respectively (p value <0.05).
Local recurrence is most common, followed by regional, nodal, and distant recurrences. Overall survival post recurrence was lowest for distant recurrences and highest for local recurrences however overall survival after primary treatment completion was highest for distant recurrence due to the late presen; however, tation of distant recurrences.
国际妇产科联盟(FIGO)分期为IB-IIA期和IIB-IVA期的宫颈癌复发率分别为28%-64%。关于不常见部位的复发模式及其与生存和预后的关系的数据匮乏。
研究远处转移患者与局部及区域淋巴结转移患者的总生存期。
进行一项回顾性研究,时间跨度为2017年1月1日至2022年12月31日。纳入接受过初次治疗后的宫颈癌患者。对局部、区域淋巴结和远处转移三组患者的生存情况进行分析。
225例患者在初次治疗结束后出现复发,其中105例(46.6%)为局部复发,46例(20.4%)为区域淋巴结复发,74例(33.3%)为远处复发。局部、区域淋巴结和不典型复发的中位复发时间分别为9个月、9个月和13个月(p值<0.05)。治疗方法包括全身化疗122例(54.2%)、节拍器治疗19例(8.4%)、姑息性放疗44例(19.5%)、姑息性手术8例(3.5%)以及最佳支持治疗30例(13.3%)。局部、淋巴结和远处复发患者复发后至治疗死亡的中位时间分别为17.0个月、18.0个月和10.0个月(p值<0.05)。初次治疗后局部、淋巴结和远处复发患者的总生存期分别为35.0个月、47.0个月和50.0个月(p值<0.05)。
局部复发最为常见,其次是区域、淋巴结和远处复发。复发后的总生存期远处复发最低,局部复发最高;然而,初次治疗完成后的总生存期远处复发最高,因为远处复发出现较晚。